David Michelson

David Michelson

Company: Regenacy Pharmaceuticals

Job title: Chief Medical Officer


HDAC6 Inhibition: A Novel Therapeutic Target for Peripheral Neuropathy & Pain 11:00 am

HDAC6 activity has an important role in regulating the intraneuronal environment of peripheral nerves In preclinical models of several different neuropathies, inhibition of HDAC6 can prevent and reverse signs of nerve dysfunction The discovery of the selective HDAC6 inhibitor ricolinostat is enabling clinical testing of HDAC6 inhibition as a treatment for neuropathic painRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.